Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Meridian Bioscience is a diagnostics & research business based in the US. Meridian Bioscience stocks (VIVO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $21.7 – an increase of 3.35% over the previous week. Meridian Bioscience employs 702 staff and has a trailing 12-month revenue of around $313.3 million.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
US Stocks
| Latest market close | $24.67 |
|---|---|
| 52-week range | $17.00 - $28.72 |
| 50-day moving average | $26.07 |
| 200-day moving average | $21.81 |
| Wall St. target price | $30.00 |
| PE ratio | 17.4504 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.36 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $24.67 from 2022-05-13
| 1 week (2022-05-06) | -5.91% |
|---|---|
| 1 month (2022-04-14) | -11.70% |
| 3 months (2022-02-16) | -3.10% |
| 6 months (2021-11-16) | 21.29% |
| 1 year (2021-05-14) | 29.37% |
|---|---|
| 2 years (2020-05-15) | 50.06% |
| 3 years (2019-05-16) | 122.45% |
| 5 years (2017-05-16) | 67.25% |
Valuing Meridian Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Meridian Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Meridian Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Meridian Bioscience shares trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Meridian Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.33. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Meridian Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Meridian Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $100.3 million.
The EBITDA is a measure of a Meridian Bioscience's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $313.3 million |
|---|---|
| Operating margin TTM | 26.98% |
| Gross profit TTM | $201.1 million |
| Return on assets TTM | 11.97% |
| Return on equity TTM | 19.22% |
| Profit margin | 19.14% |
| Book value | $7.93 |
| Market capitalisation | $1 billion |
TTM: trailing 12 months
We're not expecting Meridian Bioscience to pay a dividend over the next 12 months.
Meridian Bioscience's shares were split on a 3:2 basis on 13 May 2007. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Meridian Bioscience shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Meridian Bioscience shares which in turn could have impacted Meridian Bioscience's share price.
Over the last 12 months, Meridian Bioscience's shares have ranged in value from as little as $17 up to $28.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Meridian Bioscience's is 0.3407. This would suggest that Meridian Bioscience's shares are less volatile than average (for this exchange).
Meridian Bioscience, Inc. , a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories.
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…
Using our proprietary algorithm, we’ve found the best blue chip stocks on the TSX, NYSE and Nasdaq based on price, performance and more.
Read more…
Want to invest in satellite companies? We’ve put together a list of 6 satellite stocks you should keep your eye on.
Read more…Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
Everything we know about the ProFrac Holding Corp IPO, plus information on how to buy in.
Everything we know about the Wytec International IPO, plus information on how to buy in.
Here are some of the best stocks for inflation periods to reduce the negative impacts of inflation on your portfolio.
Choose from many account and investment types to invest in global markets, but expect to pay high commissions with HSBC InvestDirect, which doesn’t have an app.
Our Flahmingo review tells you how to buy fractional shares of some of your favourite US companies with as little as $1.
Steps to owning and managing EXPD stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PRU stock, with 24-hour and historical pricing before you buy.
